| Identification | Back Directory | [Name]
ethyl 2-[[(2S)-1-(2-phenylacetyl)pyrrolidine-2-carbonyl]amino]acetate | [CAS]
157115-85-0 | [Synonyms]
skype
SGS111
NPEP12
SGS-111
Noopept
CS-1723
SGS 111
Noopepts
Nootropices
Omberacetam
noopept powder
Noopept(GVS-111)
Nootropic GVS-111
hot selling gvs-111
Noopept Powder/GVS-111
NoopeptGVS-111Omberacetam
Noopept
Synonyms: GVS-111
99.9% Noopept Powder Nopept
Nootropic 98% Noopept powder
Ethyl 1-(phenylacetyl)-L-prolylglycinate
Ethyl N-[1-(Phenylacetyl)-L-prolyl]glycinate
GVS-111;GVS111;GVS 111;SGS-111;SGS 111;SGS111
1-(2-Phenylacetyl)-L-prolylglycine Ethyl Ester
Ethyl N-(1- (phenylacetyl) -L- prolyl) glycine
N-(1-(Phenylacetyl)-L-prolyl)glycine ethyl ester
Ethyl 1-(phenylacetyl)-L-prolylglycinate,
Noopept
Noopept,N-Phenylacetyl-L-Prolylglycine ethyl ester
Glycine, 1-(2-phenylacetyl)-L-prolyl-, ethyl ester
N - (1- (phenylacetyl) - L-prolinyl) glycine ethyl ester
ethyl 2-[[(2S)-1-(2-phenylacetyl)pyrrolidine-2-carbonyl]amin...
(S)-ethyl 2-(1-(2-phenylacetyl)pyrrolidine-2-carboxaMido)acetate
Nootropic raw powder noopept CAS157115-85-0 for memory enhancement
Noopept，ethyl 2-[[(2S)-1-(2-phenylacetyl)pyrrolidine-2-carbo，GVS-111
ethyl 2-[[(2S)-1-(2-phenylacetyl)pyrrolidine-2-carbonyl]amino]acetate
ethyl 2-[[(2s)-1-(2-phenylacetyl)pyrrolidinne-2-carbonyl]amino]acetate
N-(1-(Phenylacetyl)-L-prolyl)glycine ethyl ester SynonyMs Noopept
ethyl 2-[[(2S)-1-(2-phenylacetyl)pyrrolidine-2-carbonyl]amino]acetate/Noopept
ethyl 2-[[(2S)-1-(2-phenylacetyl)pyrrolidine-2-carbonyl]amino]acetate USP/EP/BP | [EINECS(EC#)]
1592732-453-0 | [Molecular Formula]
C17H22N2O4 | [MDL Number]
MFCD00941121 | [MOL File]
157115-85-0.mol | [Molecular Weight]
318.37 |
| Chemical Properties | Back Directory | [Melting point ]
94.0 to 98.0 °C | [Boiling point ]
547.3±50.0 °C(Predicted) | [density ]
1.202±0.06 g/cm3(Predicted) | [storage temp. ]
-20°C | [solubility ]
Soluble in DMSO (up to 25 mg/ml) | [form ]
powder | [pka]
13.41±0.20(Predicted) | [color ]
white to beige | [optical activity]
[α]/D -115 to -125°, c = 0.5 in chloroform-d | [Stability:]
Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 months. | [InChI]
InChI=1S/C17H22N2O4/c1-2-23-16(21)12-18-17(22)14-9-6-10-19(14)15(20)11-13-7-4-3-5-8-13/h3-5,7-8,14H,2,6,9-12H2,1H3,(H,18,22)/t14-/m0/s1 | [InChIKey]
PJNSMUBMSNAEEN-AWEZNQCLSA-N | [SMILES]
C(OCC)(=O)CNC(=O)[C@@H]1CCCN1C(CC1=CC=CC=C1)=O | [CAS DataBase Reference]
157115-85-0 |
| Hazard Information | Back Directory | [Description]
Noopept is the brand name for N-phenylacetyl-L-prolylglycine ethyl ester , a synthetic nootropic molecule.Noopept has a similar effect to piracetam, in that it provides a mild cognitive boost after supplementation. Noopept also provides a subtle psychostimulatory effect. | [Chemical Properties]
Noopept is a synthetic nootropic molecule grouped in the racetam class but structurally different from racetams.It is primarily water-soluble nootropic, but won't easily dissolve in water or juice. So it may help if you take it with a meal containing healthy fats. | [History]
Noopept (previously GVS-111) is a nootropic developed at the Zakusov Institute of Pharmacology (Russian Academy of Medical Sciences) by T. A. Gudasheva. It is one of several nootropics developed based on the structure of piracetam. Its advantage over piracetam is that it can be taken at a lower dose.
Noopept is a popular cognitive-enhancing supplement in the nootropic community. Proposed mechanism of actions based on preclinical studies include increasing acetylcholine signaling, increasing the expression of BDNF and NGF, protecting from glutamate toxicity, and increasing inhibitory neurotransmission in the brain.
www.alzdiscovery.org | [Uses]
Noopept is a well-known nootropic that is often suggested as a first nootropic.Noopept is over 500 times more potentthan Piracetam.Like piracetam,it is capable of enhancing memory,learning,andfocus. Noopept is also a powerful antioxidant that prevents neurological disorders andhelps the brain grow.Because of this, it is thought to improve long-term memory. The human studies have shown promising results, with potential application in the treatment of Alzheimer's disease. | [Biochem/physiol Actions]
Noopept is a nootropic and neuroprotective drug that normalizes the balance of the pro- and antioxidant systems. Noopept modulates a variety of physiological functions including cognition and anxiety. Noopept significantly weakens streptozotocin-Induced diabetes in rats. | [Mechanism of action]
Noopept is believed to amplify acetylcholine activity in the body. The reason this is noteworthy is that acetylcholine is known as the "learning transmitter" due to its impact on learning. It’s also involved in memory, cognition, and the mind-muscle connection. Noopept has also been shown to upregulate the expression of both NGF and BDNF, two important brain proteins that impact cognition and memory. Animal models also indicate that noopept modulates both the AMPA and NMDA receptors, helping to prevent glutamate toxicity, while also enhancing neuroplasticity. Noopept is also known as a powerful neuroprotectant due to its anti-inflammatory and antioxidant properties. | [Side effects]
Noopept is associated with some mild side effects based on limited clinical evidence. possible side effects of noopept included sleep disturbances (5/31 patients), irritability (3/31), and increased blood pressure (7/31) (Neznamov and Teleshova, 2009). | [Preparation]
Noopept (ethyl ester of N-phenylacetyl-L-prolylglycine) was designed as a drug at State Zakusov Institute of Pharmacology. The synthesis of the drug is based on the original hypothesis of peptide design, according to which structures similar to known psychotropic agents are reproduced using appropriate amino acids. The non-peptide prototype of Noopept is the nootropic drug Piracetam.
1. Perform the carboxylation of N-phenylacetyl-L-proline and ethyl glycine in the presence of isobutyl chloroformate.
2. Add slowly isobutyl chloroformate (1.17 g, 8.6 mmol) to a solution of N-phenylacetyl-L-proline (2.0 g, 8.6 mmol) dissolved in a mixed solvent of THF and dichloromethane (1:1; THF/dichloromethane (v/v)).3.Stir the mixture for 4 h at 0 ～5 °C
Molecular Mechanism Underlying the Action of Substituted Pro-Gly Dipeptide Noopept | [storage]
Store at -20°C | [References]
1) Ostrovskaya et al. (2007), The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer’s disease model; J. Psychopharmacol., 21 611 DOI:10.1177/0269881106071335
2) Jia et al. (2011), Neuroprotective and nootropic drug noopept rescues α-synuclein amyloid cytotoxicity; J. Mol. Biol., 414 699 DOI:10.1016/j.jmb.2011.09.044
3) Ostrovskaya et al. (2008), Noopept stimulates the expression of NGF and BDNF in rat hippocampus; Bull. Exp. Biol. Med., 146 334 DOI:10.1007/s10517-008-0297-x
4) Antipova et al. (2016), Dipeptide Piracetam Analogue Noopept Improves Viability of Hippocampal HT-22 Neurons in the Glutamate Toxicity Model; Bull. Exp. Biol. Med., 161 58 DOI:10.1007/s10517-016-3344-z
5) Ostrovskaya et al. (2014), Comparative activity of proline-containing dipeptide noopept and inhibitor of dipeptidyl peptidase-4 sitagliptin in a rat model of developing diabetes; Bull. Exp. Biol. Med., 156 342 DOI:10.1007/s10517-014-2345-z |
|
|